CN109200278A - Hysteroscope removes mucus defoaming agent and preparation method thereof - Google Patents
Hysteroscope removes mucus defoaming agent and preparation method thereof Download PDFInfo
- Publication number
- CN109200278A CN109200278A CN201811169480.9A CN201811169480A CN109200278A CN 109200278 A CN109200278 A CN 109200278A CN 201811169480 A CN201811169480 A CN 201811169480A CN 109200278 A CN109200278 A CN 109200278A
- Authority
- CN
- China
- Prior art keywords
- defoaming agent
- hysteroscope
- simethicone
- volume
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002518 antifoaming agent Substances 0.000 title claims abstract description 63
- 210000003097 mucus Anatomy 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 38
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229940083037 simethicone Drugs 0.000 claims abstract description 37
- 108090000317 Chymotrypsin Proteins 0.000 claims abstract description 34
- 229960002376 chymotrypsin Drugs 0.000 claims abstract description 34
- 239000008227 sterile water for injection Substances 0.000 claims abstract description 25
- 238000002347 injection Methods 0.000 claims abstract description 19
- 239000007924 injection Substances 0.000 claims abstract description 19
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 19
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 229960001407 sodium bicarbonate Drugs 0.000 claims abstract description 7
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 229940100688 oral solution Drugs 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 229960001275 dimeticone Drugs 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010016766 flatulence Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a kind of hysteroscopes to remove mucus defoaming agent and preparation method thereof, and the raw material components of defoaming agent include: Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection；Wherein, the ratio of the quality of the volume and chymotrypsin of Simethicone is (1~10) mL:(10~30) mg；The ratio of the volume of the volume and sodium bicarbonate injection of Simethicone is (1~10) mL:(10~30) mL；The ratio of the volume of the volume and sterilized water for injection of Simethicone is (1~10) mL:(10~40) mL.Hysteroscope provided by the invention goes mucus defoaming agent that can effectively remove bubble, increases substantially the clarity of hysteroscope, and application method is convenient, directly takes such as oral solution, clinical test there is no adverse reaction at present.
Description
Technical field
The present invention relates to medicine technology fields, and in particular to a kind of hysteroscope removes mucus defoaming agent and preparation method thereof.
Background technique
Hysteroscope is similar with electronic gastroscope, is a kind of instrument with miniature webcam, endoscope-assistant surgery be exactly utilize hysteroscope and
The operation that its related equipment carries out.But bubble existing for chyme and mucus in human body alimentary canal etc., it is clear to will affect camera lens
Therefore degree selects suitable defoaming agent bubble removing of making a return journey to be necessary.China's hysteroscope defoaming agent market vacancy at present,
Hysteroscope technology just emerges in China is currently in developing stage.Product applied by existing market only has Simethicone, and
It is completely dependent on German import.However, the product of existing market has a small amount of bubble after taking the product at present, lens articulation does not have also
Have and reach ultimate attainment, for these reasons, patient's body foreign matter cannot accurately be analyzed, cause curative effect not good enough.
Summary of the invention
For the defects in the prior art, it is an object of that present invention to provide a kind of hysteroscopes to remove mucus defoaming agent and its preparation side
Method, the defoaming agent are pure Western medicine preparations, can be used for treating in gastrointestinal tract the abdomen flatulence because of caused by the excessive gas of aggregation；?
It can be used as abdomen image check adjuvant drug (such as x-ray, ultrasonic gastroscope), postoperative use；Surfactant be can also be used as (as cleaned
Agent) poisoning when and anti-foaming agent.
To achieve the above object, technical solution provided by the invention are as follows:
The present invention provides a kind of hysteroscopes to remove mucus defoaming agent, and raw material components include: Simethicone, chymotrypsin, carbonic acid
Hydrogen sodium injection and sterilized water for injection.
Preferably, the ratio of the quality of the volume and chymotrypsin of Simethicone is (1~10) mL:(10~30) mg.
Preferably, the ratio of the volume of the volume and sodium bicarbonate injection of Simethicone is (1~10) mL:(10~30)
mL。
Preferably, the ratio of the volume of the volume and sterilized water for injection of Simethicone is (1~10) mL:(10~40)
mL。
It is further preferred that the ratio of the quality of the volume and chymotrypsin of Simethicone is 5mL:20mg；Simethicone
Volume and sodium bicarbonate injection volume ratio be 5mL:20mL；The volume of Simethicone and the body of sterilized water for injection
Long-pending ratio is 5mL:25mL.
Preferably, chymotrypsin is dry powder-shaped chymotrypsin.
The present invention also provides the preparation methods that hysteroscope removes mucus defoaming agent, comprising steps of weighing Division A League Matches of Spanish Football respectively by dosage
Silicone oil, chymotrypsin, sodium bicarbonate injection and sterilized water for injection；Sterilized water for injection is mixed into chymotrypsin, gruel is made
Protease dilution uniformly, is then successively mixed into Simethicone and sodium bicarbonate, is uniformly mixed, obtains hysteroscope and remove mucus defoaming agent.
Division A League Matches of Spanish Football silicon dimeticone/silica is a kind of stable surfactant, i.e. dimethyl silicone polymer.It can be with
Change the surface tension for the bubble being present in chyme and mucus in alimentary canal, and is allowed to decompose；The gas released can be by
Intestinal wall absorbs, and is excreted by enterocinesia.The effect of dimeticone/silica is pure physical effect, is not related to
And chemical reaction, and it is pharmacology and physiology inert substance.It is not inhaled by enteron aisle after dimeticone/silica is oral
It receives, is discharged in the form of prototype after gastrointestinal transit.Dimeticone/silica can be used for treating in gastrointestinal tract because assembling
Abdomen flatulence caused by more gases；It can be used as abdomen image check adjuvant drug (such as x-ray, ultrasonic gastroscope), postoperative use；?
Can be used as surfactant (such as detergent) poisoning when and anti-foaming agent.It can be rapidly absorbed after dimeticone/silica is oral,
And apparent first-pass metabolism is carried out, bioavilability is about 30%；Mainly in intrahepatic metabolism, with glucuronic acid and sulfuric acid knot
The metabolin and raw medicine of conjunction are excluded with urine.The 70%~90% of dosage is drained in 10~12h.
Technical solution provided by the invention, with following the utility model has the advantages that (1) hysteroscope provided by the invention goes mucus to defoam
Agent is pure Western medicine preparation, can be used for treating in gastrointestinal tract the abdomen flatulence because of caused by the excessive gas of aggregation；Also it can be used as abdomen
Portion's image check adjuvant drug (such as x-ray, ultrasonic gastroscope), postoperative use；It can also be used as surfactant (such as detergent) poisoning
When and anti-foaming agent；(2) hysteroscope provided by the invention goes mucus defoaming agent that can effectively remove bubble, increases substantially the clear of hysteroscope
Clear degree, application method is convenient, directly takes such as oral solution, clinical test there is no adverse reaction at present；(3) present invention mentions
The hysteroscope of confession goes to be rapidly absorbed after mucus defoaming agent is oral, and carries out first excessively obvious metabolism；Not yet discovery is because taking at present
The poisoning report of this defoaming agent can not be because of excessive use because the defoaming agent is complete chemical and any biological inert substance
And cause to be poisoned；The defoaming agent should shake up before, without sugar, be equally applicable to diabetic and dystrophia patient.
Additional aspect and advantage of the invention will be set forth in part in the description, and will partially become from the following description
Obviously, or practice through the invention is recognized.
Detailed description of the invention
Fig. 1 is hysteroscope one figure of detection that the present invention takes that hysteroscope goes volunteer before mucus defoaming agent；
Fig. 2 is hysteroscope two figures of detection that the present invention takes that hysteroscope goes volunteer before mucus defoaming agent；
Fig. 3 is hysteroscope three figures of detection that the present invention takes that hysteroscope goes volunteer before mucus defoaming agent；
Fig. 4 is hysteroscope one figure of detection that the present invention takes that hysteroscope goes volunteer after mucus defoaming agent；
Fig. 5 is hysteroscope two figures of detection that the present invention takes that hysteroscope goes volunteer after mucus defoaming agent；
Fig. 6 is hysteroscope three figures of detection that the present invention takes that hysteroscope goes volunteer after mucus defoaming agent.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description.The following examples are only intended to illustrate the technical solution of the present invention more clearly, therefore is intended only as example, without
It can be limited the scope of the invention with this.
Experimental method in following embodiments is unless otherwise specified conventional method.Examination as used in the following examples
Material is tested, is to be commercially available from regular shops unless otherwise specified.Quantitative test in following embodiment, is respectively provided with three
Secondary to repeat to test, data are the average value or mean+SD of three repeated experiments.
The present invention provides a kind of hysteroscope and removes mucus defoaming agent, raw material components include: Simethicone, chymotrypsin (dry powder),
Sodium bicarbonate injection and sterilized water for injection；Wherein, the ratio of the quality of the volume and chymotrypsin of Simethicone be (1~
10) mL:(10~30) mg；The ratio of the volume of the volume and sodium bicarbonate injection of Simethicone be (1~10) mL:(10~
30)mL；The ratio of the volume of the volume and sterilized water for injection of Simethicone is (1~10) mL:(10~40) mL.
In addition, including the following steps: the present invention also provides the preparation method that above-mentioned hysteroscope removes mucus defoaming agent
Weigh Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection respectively by dosage；
Sterilized water for injection is mixed into chymotrypsin, makes chymotrypsin dilution uniformly, is then successively mixed into Simethicone
And sodium bicarbonate, it is uniformly mixed, obtains hysteroscope and remove mucus defoaming agent.
Mucus defoaming agent and preparation method thereof is gone to make hysteroscope provided by the invention combined with specific embodiments below further
Explanation.
Embodiment 1
The present embodiment provides a kind of hysteroscopes to remove mucus defoaming agent, and raw material includes: Simethicone 5mL, chymotrypsin (dry powder)
20mg, sodium bicarbonate injection 20mL and sterilized water for injection 25mL.
By above-mentioned raw material, using preparation method provided by the invention, hysteroscope removes mucus defoaming agent:
Weigh Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection respectively by dosage；
Sterilized water for injection is mixed into chymotrypsin, makes chymotrypsin dilution uniformly, is then successively mixed into Simethicone
And sodium bicarbonate, it is uniformly mixed, obtains hysteroscope and remove mucus defoaming agent.The hysteroscope goes mucus defoaming agent that can store in a reservoir, needs
It is directly taken such as oral solution when wanting.
Mucus defoaming agent is gone to carry out clinical test the hysteroscope that the embodiment of the present invention 1 is prepared.It goes to glue taking hysteroscope
Before liquid defoaming agent, volunteer is allowed to detect using hysteroscope, picture when detection as shown in Figure 1, Figure 2 and Figure 3；Hysteroscope is taken to go
After mucus defoaming agent, volunteer is allowed to continue to detect using hysteroscope, picture when detection is as shown in Figure 4, Figure 5 and Figure 6.Pass through
Comparison takes hysteroscope and removes the detection figure before and after mucus defoaming agent it is found that taking after hysteroscope removes mucus defoaming agent, bubble collapse, hysteroscope
Clarity have significant raising.
Embodiment 2
The present embodiment provides a kind of hysteroscopes to remove mucus defoaming agent, and raw material includes: Simethicone 5mL, chymotrypsin (dry powder)
10mg, sodium bicarbonate injection 30mL and sterilized water for injection 15mL.
By above-mentioned raw material, using preparation method provided by the invention, hysteroscope removes mucus defoaming agent:
Weigh Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection respectively by dosage；
Sterilized water for injection is mixed into chymotrypsin, makes chymotrypsin dilution uniformly, is then successively mixed into Simethicone
And sodium bicarbonate, it is uniformly mixed, obtains hysteroscope and remove mucus defoaming agent.The hysteroscope goes mucus defoaming agent that can store in a reservoir, needs
It is directly taken such as oral solution when wanting.
Embodiment 3
The present embodiment provides a kind of hysteroscopes to remove mucus defoaming agent, and raw material includes: Simethicone 10mL, chymotrypsin (dry powder)
30mg, sodium bicarbonate injection 10mL and sterilized water for injection 30mL.
By above-mentioned raw material, using preparation method provided by the invention, hysteroscope removes mucus defoaming agent:
Weigh Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection respectively by dosage；
Sterilized water for injection is mixed into chymotrypsin, makes chymotrypsin dilution uniformly, is then successively mixed into Simethicone
And sodium bicarbonate, it is uniformly mixed, obtains hysteroscope and remove mucus defoaming agent.The hysteroscope goes mucus defoaming agent that can store in a reservoir, needs
It is directly taken such as oral solution when wanting.
Hysteroscope provided by the invention removes mucus defoaming agent, is pure Western medicine preparation, can be used for treating in gastrointestinal tract because of aggregation
Abdomen flatulence caused by excessive gas；Also it can be used as abdomen image check adjuvant drug (such as x-ray, ultrasonic gastroscope), it is postoperative to make
With；Can also be used as surfactant (such as detergent) poisoning when and anti-foaming agent.
Hysteroscope provided by the invention goes mucus defoaming agent that can effectively remove bubble, increases substantially the clarity of hysteroscope,
Application method is convenient, directly takes such as oral solution, clinical test there is no adverse reaction at present.
Pharmacokinetics: hysteroscope provided by the invention goes to be rapidly absorbed after mucus defoaming agent is oral, and carries out first mistake
Obvious metabolism.
Overdose: not yet discovery at present because taking the poisoning report of this defoaming agent because the defoaming agent be complete chemistry with
Any biological inert substance, therefore can not cause to be poisoned because of excessive use.
Points for attention: the defoaming agent should shake up before, without sugar, be equally applicable to diabetic and dystrophia is suffered from
Person.
It should be noted that unless otherwise indicated, technical term or scientific term used in this application should be this hair
The ordinary meaning that bright one of ordinary skill in the art are understood.Unless specifically stated otherwise, it otherwise illustrates in these embodiments
Component and opposite step, numerical expression and the numerical value of step are not limit the scope of the invention.It is illustrated and described herein
In all examples, unless otherwise prescribed, any occurrence should be construed as merely illustratively, not as limitation, because
This, other examples of exemplary embodiment can have different values.
In the description of the present invention, it is to be understood that, term " first ", " second " are used for description purposes only, and cannot
It is interpreted as indication or suggestion relative importance or implicitly indicates the quantity of indicated technical characteristic.Define as a result, " the
One ", the feature of " second " can explicitly or implicitly include one or more of the features.In the description of the present invention,
The meaning of " plurality " is two or more, unless otherwise specifically defined.
Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention., rather than its limitations；To the greatest extent
Pipe present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that: its according to
So be possible to modify the technical solutions described in the foregoing embodiments, or to some or all of the technical features into
Row equivalent replacement；And these are modified or replaceed, various embodiments of the present invention technology that it does not separate the essence of the corresponding technical solution
The range of scheme should all cover in protection scope of the present invention.
Claims (7)
1. a kind of hysteroscope removes mucus defoaming agent, which is characterized in that raw material components include:
Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection.
2. hysteroscope according to claim 1 removes mucus defoaming agent, it is characterised in that:
The ratio of the volume of the Simethicone and the quality of the chymotrypsin is (1~10) mL:(10~30) mg.
3. hysteroscope according to claim 1 removes mucus defoaming agent, it is characterised in that:
The ratio of the volume of the Simethicone and the volume of the sodium bicarbonate injection is (1~10) mL:(10~30) mL.
4. hysteroscope according to claim 1 removes mucus defoaming agent, it is characterised in that:
The ratio of the volume of the Simethicone and the volume of the sterilized water for injection is (1~10) mL:(10~40) mL.
5. hysteroscope according to claim 1 removes mucus defoaming agent, it is characterised in that:
The ratio of the volume of the Simethicone and the quality of the chymotrypsin is 5mL:20mg；
The ratio of the volume of the Simethicone and the volume of the sodium bicarbonate injection is 5mL:20mL；
The ratio of the volume of the Simethicone and the volume of the sterilized water for injection is 5mL:25mL.
6. hysteroscope according to claim 1 removes mucus defoaming agent, it is characterised in that:
The chymotrypsin is dry powder-shaped chymotrypsin.
7. the preparation method that hysteroscope described in any one of claims 1-6 removes mucus defoaming agent, which is characterized in that comprising steps of
Weigh Simethicone, chymotrypsin, sodium bicarbonate injection and sterilized water for injection respectively by dosage；
The sterilized water for injection is mixed into the chymotrypsin, makes the chymotrypsin dilution uniformly, is then successively mixed into
The Simethicone and the sodium bicarbonate are uniformly mixed, obtain the hysteroscope and remove mucus defoaming agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811169480.9A CN109200278A (en) | 2018-10-08 | 2018-10-08 | Hysteroscope removes mucus defoaming agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811169480.9A CN109200278A (en) | 2018-10-08 | 2018-10-08 | Hysteroscope removes mucus defoaming agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200278A true CN109200278A (en) | 2019-01-15 |
Family
ID=64983308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811169480.9A Pending CN109200278A (en) | 2018-10-08 | 2018-10-08 | Hysteroscope removes mucus defoaming agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200278A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110314134A (en) * | 2019-01-24 | 2019-10-11 | 北京歌斐医疗器械有限公司 | A kind of gastrointestinal endoscopy auxiliary water and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804199A (en) * | 2010-03-30 | 2010-08-18 | 四川健能制药有限公司 | Pharmaceutical composition used for alimentary canals and application thereof |
| WO2012067481A2 (en) * | 2010-11-16 | 2012-05-24 | Posi Visionary Solutions, Llp | Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN104353086A (en) * | 2014-09-29 | 2015-02-18 | 诸暨市鹏天医疗器械有限公司 | Gastroscope mucilage compound preparation |
| CN106062162A (en) * | 2014-02-26 | 2016-10-26 | 宝洁公司 | Antifoam composition |
-
2018
- 2018-10-08 CN CN201811169480.9A patent/CN109200278A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804199A (en) * | 2010-03-30 | 2010-08-18 | 四川健能制药有限公司 | Pharmaceutical composition used for alimentary canals and application thereof |
| WO2012067481A2 (en) * | 2010-11-16 | 2012-05-24 | Posi Visionary Solutions, Llp | Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN106062162A (en) * | 2014-02-26 | 2016-10-26 | 宝洁公司 | Antifoam composition |
| CN104353086A (en) * | 2014-09-29 | 2015-02-18 | 诸暨市鹏天医疗器械有限公司 | Gastroscope mucilage compound preparation |
Non-Patent Citations (2)
| Title |
|---|
| 孙雪龙等: "糜蛋白酶和链蛋白酶在胃镜检查中对图像清晰度影响的临床研究", 《中国血液流变学杂志》 * |
| 陈新波等: "二甲硅油散和糜蛋白酶联合应用在胃镜检查中的价值", 《重庆医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110314134A (en) * | 2019-01-24 | 2019-10-11 | 北京歌斐医疗器械有限公司 | A kind of gastrointestinal endoscopy auxiliary water and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240130976A1 (en) | Pharmaceutical Formulation of Odevixibat | |
| Sanderson et al. | Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. | |
| Bauer et al. | Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism | |
| AU2019290338A1 (en) | Pharmaceutical formulation of odevixibat | |
| EP2897594B1 (en) | Pharmaceutical composition | |
| CN101804199B (en) | Pharmaceutical composition used for alimentary canals and application thereof | |
| WO2012102799A2 (en) | Method, composition and package for bowel cleansing | |
| JP2011500711A (en) | Intestinal laxative and its use | |
| US6509169B2 (en) | Detection of Helicobacter pylori | |
| Bezjak | Evaluation of a new technic for sampling duodenal contents in parasitologic diagnosis | |
| CN109200278A (en) | Hysteroscope removes mucus defoaming agent and preparation method thereof | |
| CN102688251B (en) | Simethicone composition | |
| HK1038509B (en) | Method and system for production and collection of lavage induced stool (lis) for chemical and biologic tests of cells | |
| KR920009544B1 (en) | Peroxidase Detection Method and Detection Reagent | |
| CN1263516C (en) | Pharmaceutical preparations for the diagnosis of Helicobacter pylori infection | |
| CN102091054A (en) | Progesterone preparation composite and preparation method thereof | |
| CN120284985A (en) | A simethicone oral preparation composition and its preparation method and application | |
| RU2629838C2 (en) | Oil-based pharmaceutical composition for gastrointestinal diseases treatment | |
| CN107550884B (en) | A kind of Doneppezil Hydrochloride capsule and preparation method thereof | |
| Noory et al. | Steps for development of a dissolution test for sparingly water-soluble drug products | |
| CN107441508B (en) | Simethicone composition | |
| Tian et al. | Better out than in: a case series of retained rectal foreign bodies in a New York Community Hospital | |
| Helman et al. | Jejunal monosaccharide, water, and electrolyte transport in patients with chronic pancreatitis. | |
| CN107496354A (en) | Simethicone fluid composition | |
| CN108578377A (en) | A kind of Fluconazole piece and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |
|
| RJ01 | Rejection of invention patent application after publication |